SeaStar Medical Holdings (NASDAQ:ICU), a company that specializes in medical devices, is leveraging its breakthrough designation to help critically ill patients.

Eric Schlorff CEO SeaStar Medical Holding Corp. ICUBenzinga All-Access recently featured. 

SeaStar Medical aims to provide life-saving organ solutions for critically ill patients suffering from inflammation. QUELIMMUNE is the first treatment that SeaStar Medical has developed. It was approved last year by the U.S. Food and Drug Administration to treat children with AKI due to sepsis. 

SeaStar has also begun a study to evaluate the efficacy and safety of its proprietary Selective Cytopheretic Devices (SCDs) in treating adults with AKI. Schlorff estimates that the market potential for this trial is $4.5 billion per year. SeaStar has been awarded Breakthrough Device Status by the FDA for several of its devices. The company is confident that their therapy will be able to treat a wide range of serious and life-threatening diseases. 

Click here to watch the complete interview 

The featured image is by Annie Spratt On, Unsplash.

The content of this post is sponsored. This post is only for informative purposes and does not offer investment advice.